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SUMMARY
Atypical haemolytic uraemic syndrome (aHUS) often leads to end-stage renal
disease (ESRD) and kidney transplantation; graft loss rates are high due to dis-
ease recurrence. A post hoc analysis of four prospective clinical trials in aHUS
was performed to evaluate eculizumab, a terminal complement inhibitor, in
patients with native or transplanted kidneys. The trials included 26-week
treatment and extension periods. Dialysis, transplant and graft loss were evalu-
ated. Study endpoints included complete thrombotic microangiopathy
(TMA) response, TMA event-free status, haematologic and renal parameters
and adverse events. Of 100 patients, 74 had native kidneys and 26 in the trans-
plant subgroup had a collective history of 38 grafts. No patients lost grafts and
only one with pre-existing ESRD received a transplant on treatment. Efficacy
endpoints were achieved similarly in both subgroups. After 26 weeks, mean
absolute estimated glomerular filtration rate increased from baseline to 61 and
37 ml/min/1.73 m2 in native (n = 71; P < 0.0001) and transplanted kidney
(n = 25; P = 0.0092) subgroups. Two patients (one/subgroup) developed
meningococcal infections; both recovered, one continued therapy. Eculizu-
mab was well tolerated. Eculizumab improved haematologic and renal out-
comes in both subgroups. In patients with histories of multiple graft losses,
eculizumab protected kidney function.
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Introduction
Atypical haemolytic uraemic syndrome (aHUS) is a
rare, progressive and potentially life-threatening disease
caused by chronic, uncontrolled activation of the com-
plement alternative pathway [1,2]. Complement gene
abnormalities occur in approximately 50–70% of
patients [2,3]. The resulting complement dysregulation
leads to thrombotic microangiopathy (TMA), which is
generally characterized by haemolytic anaemia, throm-
bocytopenia and acute kidney injury [1] and frequently
other organ impairment [2,3]. Patients who remain
untreated are at lifelong risk for end-stage renal disease
(ESRD), other organ dysfunction and premature death
[2–4]. Patients may require kidney transplantation [2],
and post-transplant TMA occurs in approximately 68%
of patients with transplanted kidneys and is associated
with a high rate of graft failure within 5 years (64%)
[5]. Graft loss due primarily to clinical manifestations
of aHUS has invalidated plasma exchange/plasma infu-
sion (PE/PI) as a viable management option for patients
with aHUS and renal transplants [5].
Eculizumab (Soliris; Alexion Pharmaceuticals Inc.,
New Haven, CT, USA) is a fully humanized monoclonal
antibody that binds to terminal complement protein
C5, inhibiting its cleavage into C5a, a potent anaphyla-
toxin, and C5b, which goes on to form the membrane
attack complex (C5b-9) [6,7]. It is the only approved
treatment for patients with aHUS [6,7]. Eculizumab has
been demonstrated to inhibit complement-mediated
TMA and to be well tolerated in four prospective
clinical trials in paediatric and adult patients with aHUS
[8–11].
Extent of previous renal injury is known to influence
changes in renal function in patients with aHUS [12]
and particularly in those with transplanted kidneys [13].
The objective of the current analysis was to characterize
the efficacy and safety of eculizumab in patients with
native and transplanted kidneys in a pooled population
from the eculizumab clinical trial programme in aHUS,
to understand potential differences in these patient sub-
groups.
Materials and methods
A post hoc analysis was conducted on the pooled results
of four prospective, open-label, nonrandomized, single-
arm, multicenter, phase 2 clinical trials, which were
reported previously (NCT00844545/NCT00844844 and
NCT00838513/NCT00844428 [8,9], NCT01193348 [10]
and NCT01194973 [11]). These trials assessed the
efficacy and safety of eculizumab in patients with aHUS
over 26-week treatment periods followed by extension
periods. All patients received meningococcal vaccination
and/or antibiotic prophylaxis before initiation of eculi-
zumab. Eculizumab was administered either as follows:
(i) intravenously 900 mg every week for 4 weeks,
1200 mg at the fifth week, then 1200 mg every 2 weeks;
or (ii) for paediatric patients, at doses prespecified by
body weight.
Demographic and baseline characteristics were sum-
marized by transplant subgroup (native and trans-
planted kidneys) and for all patients. Differences
between native kidney and transplant subgroups at
baseline were tested using Wilcoxon rank sum tests for
continuous variables and Fisher exact tests for categori-
cal variables. Dialysis, transplant and graft loss statuses
were evaluated at baseline and prospectively. Efficacy
endpoints for this post hoc analysis were defined by the
study protocols and included complete TMA response
[platelet count ≥150 9 109/l, lactate dehydrogenase
(LDH) levels less than the upper limit of normal and
≥25% decrease from baseline in serum creatinine level],
TMA event-free status (no decrease in platelet
count >25% from baseline, no PE/PI and no new dialy-
sis), haematologic normalization (platelet count
≥150 9 109/l and LDH levels less than the upper limit
of normal), mean change from baseline in platelet
count, mean estimated glomerular filtration rate
(eGFR), mean proteinuria level and chronic kidney dis-
ease (CKD) improvement by ≥1 stage. Categorical end-
points were required to be sustained for two or more
consecutive measurements obtained ≥4 weeks apart, and
P values between subgroups were calculated using Fisher
exact tests. Time to achievement of endpoints also was
assessed. Platelet counts and eGFR values were summa-
rized descriptively at each visit by transplant subgroup.
Comparisons between postdose visits and baseline were
made within each subgroup using paired t-tests. P val-
ues were reported for descriptive purposes only, rather
than to imply statistical significance. Safety was assessed
by reported treatment-emergent adverse events
(TEAEs).
Results
A total of 100 patients were included in this post hoc,
intention-to-treat analysis, comprising 74 patients with
native kidneys and 26 patients with transplanted kidneys
at baseline (Fig. 1). There were significant differences at
baseline between the native and transplanted kidney
subgroups (Table 1). Patients with transplanted kidneys
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were older (median age: 41.5 vs. 24.0 years; P = 0.0002)
and had a longer time from aHUS diagnosis to screen-
ing (median: 34.8 vs. 0.85 months; P < 0.0001), lower
proportion of patients with their first TMA manifesta-
tion (27% vs. 69%; P = 0.0002) and lower proportion
of patients on dialysis at baseline (23% vs. 50%;
P = 0.0214).
Median (range) duration of eculizumab treatment
was 71 (0–186) weeks overall; 64 (0–186) weeks in
patients with native kidneys and 100 (3–170) weeks in
patients with transplanted kidneys. The 26 kidney trans-
plant recipients received a total of 38 grafts before initi-
ating eculizumab (Fig. 2). No patient experienced graft
loss after initiating eculizumab. One patient with ESRD
for more than 4 months before inclusion into the study
received a kidney transplant 217 days after initiation of
eculizumab, as described previously [8].
The majority of patients with both native and trans-
planted kidneys achieved endpoints by end of study
(Table 2), including complete TMA response (74% and
65%, respectively), TMA event-free status (93% and
88%, respectively) and haematologic normalization
(96% and 85%, respectively). Compared with patients
with native kidneys, those with transplanted kidneys
required longer time to reach complete TMA response
(median time: 66 and 98 days for n = 55 patients with
native kidneys and n = 17 patients with transplanted
kidneys who attained response, respectively) and haema-
tologic normalization (median time: 33 and 56 days for
n = 71 patients with native kidneys and n = 22 patients
with transplanted kidneys who attained the endpoint,
respectively).
In addition, Kaplan–Meier methods were used to
compute median time to achievement of the endpoints,
treating nonresponders as censored observations. For
complete TMA response, the medians were 85 and
287 days for patients with native and transplanted kid-
neys, respectively (Fig. 3). Median time to haematologic
normalization with Kaplan–Meier methods (33 and
55 days, respectively, for patients with native and trans-
planted kidneys; Fig. 4) was similar to that reported
above.
Patients with platelet count <150 9 109/l at baseline in
both subgroups (native kidneys, n = 51; transplanted
kidneys, n = 14) had significant improvements after initi-
ation of eculizumab. After 1 week of treatment, the mean
[standard deviation (SD)] change from baseline in plate-
let count was 115 (99) 9 109/l in patients with native
kidneys (n = 50; P < 0.0001) and 104 (141) 9 109/l in
patients with transplanted kidneys (n = 14; P = 0.0161).
The mean (SD) change from baseline after 26 weeks was
165 (98) 9 109/l (n = 48; P < 0.0001) and 116
(126) 9 109/l (n = 13; P = 0.006), respectively. After
18 months, the mean (SD) change from baseline was 136
(69) 9 109/l (n = 20; P < 0.0001) and 83 (94) 9 109/l
(n = 10; P = 0.0211), respectively.
Mean absolute eGFR values also increased significantly
with eculizumab treatment in both subgroups. Compared
with baseline, the mean (SD) absolute eGFR value after
26 weeks of treatment was 61 (41) ml/min/1.73 m2
[mean (SD) change from baseline, 38 (36) ml/min/
1.73 m2] in patients with native kidneys (n = 71;
P < 0.0001) and 37 (25) ml/min/1.73 m2 [mean (SD)
change from baseline, 11 (20) ml/min/1.73 m2] in
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Figure 1 Patient disposition.
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patients with transplanted kidneys (n = 25; P = 0.0092).
The mean (SD) eGFR value after 18 months was 66
(31) ml/min/1.73 m2 [mean (SD) change from baseline,
44 (34) ml/min/1.73 m2] in patients with native kidneys
(n = 35; P < 0.0001) and 42 (27) ml/min/1.73 m2 [mean
(SD) change from baseline, 13 (23) ml/min/1.73 m2] in
patients with transplanted kidneys (n = 20; P = 0.0188).
Overall, proteinuria decreased with eculizumab treat-
ment in both subgroups. At baseline, mean (SD) pro-
teinuria levels were 200 (294) mg/dl in patients with
native kidneys (n = 54) and 209 (379) mg/dl in patients
with transplanted kidneys (n = 21). After 26 weeks,
mean (SD) levels were 53 (52) mg/dl (n = 49) and 74
(68) mg/dl (n = 20), respectively. After 18 months of
eculizumab, patients with native kidneys (n = 30) had a
mean (SD) proteinuria level of 46 (66) mg/dl and for
patients with transplanted kidneys (n = 17), the pro-
teinuria level was 52 (72) mg/dl.
Chronic kidney disease improvement by ≥1 stage
occurred in 47 patients (64%) with native kidneys and
13 patients (50%) with transplanted kidneys at
26 weeks. At study end, 55 patients (74%) with native
kidneys and 15 patients (58%) with transplanted kid-
neys had CKD improvement by ≥1 stage.
Eculizumab was well tolerated in both patient sub-
groups, with most TEAEs being of mild or moderate
severity. TEAEs judged at the discretion of the investiga-
tor to be related to eculizumab treatment were reported
Time from aHUS diagnosis to eculizumab treatment Known time on eculizumab treatment
Kidney transplantTime from transplant to eculizumab treatment
Eculizumab treatment (months)Time since aHUS diagnosis (months)
7525
Patient Mutation
CFH
ND
CFI
ND
CFH
ND
ND
C3, CFI
CFH, CFI, CFHR3/1
CFH, CFHR3/1
CFI
CFI
CFI
C3
C3
CFHR3/1
CFHR3/1
ND
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ND
ND
ND
ND
ND
ND
*5
6
7
8
9
10
11
12
13
14
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21
4
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15
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26
27 ND
300 0150200250 100 50 50
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***
***
***
***
***
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Figure 2 Timing of kidney transplant in relation to aHUS diagnosis and eculizumab treatment. Patients 6, 7, 17 and 19 were diagnosed with
aHUS prior to eculizumab initiation. *Patient withdrew due to an adverse event. **Approximate duration from diagnosis to first dose of eculi-
zumab. After kidney transplantation on day 217, the patient’s renal data were censored [8]. ***Did not enter long-term follow-up; no further
information is available. aHUS, atypical haemolytic uraemic syndrome; CFH, complement factor H; CFHR3/1, CFH-related protein 3/1 polymor-
phism; CFI, complement factor I; ND, none detected.
Table 2. Efficacy outcomes at end of study.
Endpoint
All patients
(N = 100)
Native
kidney
(n = 74)
Transplanted
kidney
(n = 26) P value*
Complete TMA response
n (%) 72 (72) 55 (74) 17 (65) 0.4486
95% CI 62–81 63–84 44–83
TMA event-free status
n (%) 92 (92) 69 (93) 23 (88) 0.6433
95% CI 87–98 87–99 74–99
Haematologic normalization
n (%) 93 (93) 71 (96) 22 (85) 0.0727
95% CI 86–97 89–99 65–96
CI, confidence interval; TMA, thrombotic microangiopathy.
*P values between native kidney and transplant subgroups
were calculated using Fisher exact tests.
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in 35 patients (47%) with native kidneys and 14 (53%)
with transplanted kidneys. Related TEAEs occurring in
>5% of the subgroup population included alopecia,
headache, leukopenia and vomiting in the native kidney
subgroup and BK virus infection, headache, leukopenia,
lymphopenia, pyelonephritis and urinary tract infection
in the transplanted kidney subgroup. Severe TEAEs con-
sidered by the investigator to be possibly/probably
related to eculizumab treatment included dyspnoea
(n = 1), gonococcal genitourinary tract infection
(n = 1), hypertension (n = 1), influenza (n = 1), peri-
tonitis (n = 1) and venous thrombosis (n = 1) in the
native kidney subgroup and meningococcal meningitis
(n = 1), pyelonephritis (n = 2), renal impairment
(n = 1) and vein disorder (n = 1) in the kidney trans-
plant subgroup. Overall, two cases of meningococcal
infection occurred in the pooled population and were
reported previously [11]. One patient was a transplant
recipient and the other had native kidneys. Both
patients had received meningococcal vaccinations
against serogroups A, C, W and Y, but neither had
received long-term prophylactic antibiotics. Both
patients recovered with antibiotic therapy, and the
patient with native kidneys continued to receive eculizu-
mab. One death occurred in a patient in the kidney
transplant subgroup, as reported previously [9], and
was attributed to complications from intestinal haemor-
rhage that were deemed unrelated to eculizumab.
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Figure 3 Kaplan–Meier analysis of time to complete TMA response. TMA, thrombotic microangiopathy.
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Figure 4 Kaplan–Meier analysis of time to haematologic normalization.
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Discussion
This pooled post hoc analysis demonstrates the efficacy and
safety of eculizumab in improving renal function and
haematologic parameters in the aHUS clinical trial pro-
gramme in patients with native kidneys and those with
transplanted kidneys. The majority of patients in both sub-
groups achieved efficacy endpoints as well as significant
increases in platelet counts and improvements in eGFR
that were maintained over 18 months of follow-up. Gains
in eGFR were also associated with improvements in CKD
stage and proteinuria for patients in both subgroups.
Overall, patients with transplanted kidneys had lower
magnitudes of improvement in renal function and
platelet count, perhaps due, in some measure, to factors
related to transplantation (e.g. ischaemia and
reperfusion injury, delayed graft function, potential
nephrotoxicity of immunosuppressive agents). Time to
complete TMA response was longer in this subgroup
compared with patients with native kidneys due to the
renal requirement (i.e. ≥25% decrease from baseline in
serum creatinine level) of this composite endpoint.
Median time to complete TMA response, especially in
patients with transplanted kidneys, was longer with
Kaplan–Meier methods compared with descriptive sum-
mary. This is likely due to the small number of patients
in the transplanted kidney group and the censoring pat-
tern. A recent publication from a Kidney Disease:
Improving Global Outcomes (KDIGO) Controversies
Conference [14] states that for patients with high risk
of disease recurrence, recovery of renal function in
grafts may be limited compared with native kidneys.
Additionally, nine (35%) of the kidney transplant recip-
ients in this cohort originated from the study in which
the patients with aHUS had been deemed responsive to
PE/PI (NCT00838513/NCT00844428) [8]. Eleven (42%)
of the transplant patients had normal platelet counts at
baseline, which may account, at least in part, for a
lower magnitude of platelet count improvement com-
pared with patients with native kidneys.
Graft loss is known to occur at a high rate in patients
with aHUS and previously transplanted kidneys [5,15],
due primarily to recurrence of TMA within the trans-
planted kidney. Eculizumab therapy has been shown to
be effective in preventing and treating aHUS recurrence
post-transplant in a retrospective study of 22 patients
[13]. In the current analysis, eight of 26 patients (31%)
with transplanted kidneys had a history of one or more
kidney transplants before treatment initiation. Of impor-
tance, no patient who received a transplant before initiat-
ing eculizumab experienced graft loss while on therapy,
with a median eculizumab exposure of 71 weeks. The
patient who required a kidney transplant after starting
eculizumab therapy had pre-existing ESRD. Following
the KDIGO Controversies Conference, Goodship et al.
[14] recommend that patients with aHUS and kidney
transplants, especially those who have lost previous grafts,
should not discontinue eculizumab therapy.
While outcomes for patients treated with eculizumab
who received transplants were favourable in the current
study and previously published observational studies
[13,16,17] and case reports [18–30], care should be taken
when applying these findings in clinical practice. In limited
case studies, mainly with reduced dosages of eculizumab
compared with the approved treatment regimen, patients
lost grafts or otherwise had kidney injury progression
[13,16,17]. In addition, a complex case of aHUS has been
reported in a paediatric patient with complement factor H
mutation who initiated eculizumab and was transplanted
after a severe disease course approximately 5 years after
the initial aHUS diagnosis. However, the patient had
disease recurrence while receiving sufficient eculizumab
dose and eventually required a liver transplant [31]. There-
fore, additional studies in larger patient populations and
outside of the clinical trials are needed to more fully
evaluate the efficacy of eculizumab. The global aHUS
Registry was initiated in 2012 to evaluate long-term disease
outcomes in eculizumab-treated and untreated patients
[32]. Ongoing analyses include timing of eculizumab
initiation and effects on rates of TMA and dialysis require-
ments in patients with aHUS undergoing kidney transplan-
tation. Preliminary findings suggest that initiating
eculizumab pretransplant compared with post-transplant
may be associated with better outcomes [33].
A previous pooled post hoc analysis [34] of the clinical
trial programme for eculizumab in aHUS demonstrated
that early (i.e. within 7 days of presentation) initiation of
treatment was associated with optimal renal outcomes.
Younger age and certain laboratory criteria (i.e. relatively
higher LDH and lower haemoglobin levels) were also
independently associated with better renal outcomes on
eculizumab. In the current analysis, age and baseline char-
acteristics pertaining to length of disease history (i.e. time
from diagnosis to study screening and history of previous
TMA manifestations) differed significantly between native
and transplanted kidney subgroups, although these differ-
ences may have been expected due to study eligibility cri-
teria. More studies are needed to determine the potential
role of such demographic and baseline clinical characteris-
tics on renal outcomes in aHUS.
Eculizumab was well tolerated in patients with native
and transplanted kidneys, with most TEAEs reported as
Transplant International 2017; 30: 1275–1283 1281
ª 2017 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.
Eculizumab in aHUS by transplant status
mild or moderate. As discussed previously [9], there was
one patient death following complications from intestinal
haemorrhage that were deemed unrelated to eculizumab.
The two meningococcal infections that occurred in the
study in an exclusively adult population with aHUS [11]
underscore the need for vigilant monitoring of meningo-
coccal symptoms in patients receiving eculizumab ther-
apy. Overall, mounting evidence from the clinical trial
programme in aHUS [8–11] and a 10-year study of
patients with paroxysmal nocturnal haemoglobinuria
[35] suggests that meningococcal infection is an uncom-
mon event with eculizumab therapy.
For patients with aHUS, optimal disease management
should minimize potential for organ injury, reduce need
for transplantation and protect against graft loss while
improving clinical outcomes. This analysis demonstrated
that eculizumab therapy was associated with improve-
ments in renal and haematologic outcomes, regardless
of transplant status. Eculizumab treatment in patients
with a history of transplant reduces the risk of graft loss
due to aHUS recurrence and enables ongoing improve-
ments in renal graft function.
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